Quarterly report pursuant to Section 13 or 15(d)

Note 10 - Shareholders' Equity

v3.24.1.u1
Note 10 - Shareholders' Equity
 3 Months Ended
Mar. 31, 2024
Notes to Financial Statements  
Equity [Text Block]

10.

Shareholders’ Equity

 

Authorized capital shares

 

DiaMedica has authorized share capital of an unlimited number of voting common shares, and the shares do not have a stated par value. Common shareholders are entitled to receive dividends as declared by the Company, if any, and are entitled to one vote per share at the Company’s annual general meeting and any extraordinary or special general meeting.

 

 

Equity issued during the three months ended March 31, 2024

 

During the three months ended March 31, 2024, 5,916 common shares were issued upon the vesting and settlement of restricted stock units.

 

Equity issued during the three months ended March 31, 2023

 

During the three months ended March 31, 2023, 17,621 common shares were issued in settlement of deferred share units and 4,289 common shares were issued upon the vesting and settlement of restricted stock units.

 

Shares reserved

 

Common shares reserved for future issuance are as follows:

 

   

March 31, 2024

  

Common shares issuable upon exercise of employee and non-employee stock options

     4,259,763  

Common shares issuable upon settlement of deferred stock units

     284,886  

Common shares issuable upon vesting and settlement of restricted stock units

     17,744  

Shares available for grant under the Amended and Restated 2019 Omnibus Incentive Plan

     732,574  

Shares available for grant under the 2021 Employment Inducement Incentive Plan

     110,000  

Total

     5,404,967